Risk for clinical deterioration is high, but treatment tends to lead to stability or improvement.
Spinal cord arteriovenous malformations (AVMs) are an important, albeit uncommon, etiology for myelopathy. They can cause spinal cord compression, venous congestion, and sometimes hemorrhage. The gold standard for diagnosis is angiography, but sometimes flow voids can be observed on MRI. Investigators detail their experience with 466 patients with symptomatic AVMs identified through a Chinese database.
Median follow-up was 12 months. Average age of onset was 25 years; onset was acute in 57% of cases and gradual in 43%. Spontaneous improvement or recovery of neurologic deficits occurred in 210 patients, typically in the first month, and was more common in acute-onset than gradual-onset patients (77% vs. 3%). Lesion location was most commonly …
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)